#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Anaphylactic symptoms and anaphylactic shock


Authors: Irena Krčmová;  Jakub Novosad
Authors place of work: Ústav klinické imunologie a alergologie LF UK a FN Hradec Králové
Published in the journal: Vnitř Lék 2019; 65(2): 149-156
Category:

Summary

Anaphylactic symptoms and anaphylactic shock are serious, rapidly developing and potentially fatal systemic reactions occurring after contact with the trigger, followed by release of a number of substances that affect vascular permeability, smooth muscle tone of blood vessels and bronchi with activation of the systemic inflammatory cascade. From a pathophysiological point of view, it can be an IgE-mediated immune response followed by massive release of biologically active mediators from mast cells and basophils (IgE dependent). If the mastocyt/basophil is degranulated via a direct IgE-free pathway, it is non-allergic (non-IgE dependent, anaphylactoid anaphylaxis). The diagnosis of anaphylaxis is determined on the basis of clinical criteria, taking into account the need to initiate therapy in a life-threatening condition without delay. Adrenaline is the first-line drug in the treatment of anaphylaxis and there is no contraindication to its use. Early provision of venous intake is essential for the patient to develop hypotension.

Keywords:

Adverse events – IgE dependent anaphylaxis – non IgE dependent anaphylaxis – management of anaphylaxis


Zdroje
  1. Muraro A, Roberts, G, Worm M et al. Anaphylaxis: guidelines from European Academy of Allergy and Clinical Immunology. Allergy 2014; 69(8): 1026–1045. Dostupné z DOI: <http://doi: 10.1111/all.12437>.

  2. Petrů V. Chyby a omyly v diagnostice a léčbě anafylaxe. Postgrad Med 2017; 19(3): 285–290.

  3. Tanno LK, Ganem F, Demoly P et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67(6): 783–789. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398–9995.2012.02829.x>.

  4. Panesar SS, Nwaru B, Hickstein L et al. The epidemiology of anaphylaxis in Europe: protocol for a systematic review. Clin Transl Allergy 2013; 3(1): 9. Dostupné z DOI: <http://dx.doi.org/10.1186/2045–7022–3-9>.

  5. Worm A, Moneret-Vautrin AM, Scherer K et al. First European data from the network of severe allergic reaction (NORA). Allergy 2014; 69(10): 1397–1404. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12475>.

  6. Finkelman F, Khodoun M, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol 2016; 137(6): 1674–1680. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2016.02.015>.

  7. Petrů V, Krčmová I. Anafylaktická reakce. Maxdorf Jessenius: Praha 2006: 3–95. ISBN 80–7345–099–2.

  8. Krejsek J, Andrýs C, Krčmová I. Imunologie člověka. Garamon: Hradec Králové: 2016: 213–221. ISBN 978–80–86472–74–4.

  9. Mehr S, Liew WK, Tey D et al. Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy 2009; 39(9): 1390–1396. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2222.2009.03276.x>.

  10. Park HJ, Kim SH. Factors associated with shock in anaphylaxis. Am J Emerg Med 2012; 30(9): 1674–1678. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajem.2012.01.015>.

  11. Simons FER, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124(2): 301–306. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2009.03.050>.

  12. Soar J, Perkins GD, Abbas G et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 2010; 81(10): 1400–1433. Dostupné z DOI: <http://dx.doi.org/10.1016/j.resuscitation.2010.08.015>.

  13. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001–2006. J Allergy Clin Immunol 2007; 119(4): 1016–1018. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2006.12.622>.

  14. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30(8): 1144–1150.

  15. Braganza SC, Acworth JP, McKinnon DR et al. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 2006; 91(2): 159–163. Dostupné z DOI: <http://dx.doi.org/10.1136/adc.2004.069914>.

  16. Calvani M, Cardinale F, Martelli A et al. Risk factors for severe pediatric food anaphylaxis in Italy. Pediatr Allergy Immunol 2011; 22(8): 813–819. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1399–3038.2011.01200.x>.

  17. Gonzalez-Perez A, Aponte Z, Vidaurre CF et al. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom databas review. J Allergy Clin Immunol 2010; 125(5): 1098–1104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2010.02.009>.

  18. Hamilton MJ, Hornick JL, Akin C et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011; 128(1): 147–152. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2011.04.037>.

  19. Moneret-Vautrin DA. Drugs as risk factors of food anaphylaxis in adults. Facteurs de risque d’anaphylaxie alimentaire severe Role confirme de certaines classes de medicaments. Med Sci (Paris) 2010; 26(8–9): 719–723. Dostupné z DOI: <http://dx.doi.org/10.1051/medsci/2010268–9719>.

  20. Niggemann B, Beyer K. Time for a new grading system for allergic reaction? Allergy 2016; 71(2): 135–136. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12765>.

  21. De Schryver S, Halbrich M, Clarke A et al. Tryptase levels in children presenting with anaphylaxis. Temporal trends and associated factors. J Allergy Clin Immunol 2016; 137(4): 1138–1142. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2015.09.001>.

  22. Noimark L, Wales J, Du Toit G et al. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy 2012; 42(2): 284–292. Dostupné z DOI: <http://doi: 10.1111/j.1365–2222.2011.03912.x>.

  23. Lieberman P. The 10-second rule and other myths about epinephrine and autoinjectors. Ann Allergy Asthma Immunol 2011; 107(3): 189–190. Dostupné z DOI: <http://doi 10.1016/j.anai.2011.07.007>.

  24. Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108(5): 871–873. Dostupné z DOI: <http:// 10.1067/mai.2001.119409>.

  25. Simons F, Ardusso L, Bilo M et al. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12(4): 389–399. Dostupné z DOI: <http://dx.doi.org/10.1097/ACI.0b013e328355b7e4>.

  26. Lin RY, Curry A, Pesola GR et al. Improved outcomes outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36(5): 462–468. Dostupné z DOI: <http://dx.doi.org/10.1067/mem.2000.109445>.

  27. Thomas M. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22(4): 272–273. Dostupné z DOI: <http://dx.doi.org/10.1136/emj.2005.023507>.

  28. Váchová M., Panzner P. Diagnostika alergie na Hymenopter. Alergie 2017; 19(3): 173–180.

  29. Gagné C. Peanut OIT Therapy Sees Success, Boosting Hope for FDA Approval. Allergic Living: Food Allergy News 2018. Dostupné z WWW: <https://www.allergicliving.com/2018/02/20/peanut-oit-therapy-sees-success-boosting-hope-for-fda-approval/>.

Štítky
Diabetology Endocrinology Internal medicine
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#